@article{049bdcb1b8e04a86b64f4a463ef6a425,
title = "Safety, Tolerability, and Pharmacokinetics of ARC-520 Injection, an RNA Interference-Based Therapeutic for the Treatment of Chronic Hepatitis B Virus Infection, in Healthy Volunteers",
keywords = "RNA interference, RNAi, hepatitis B, pharmacokinetics, pharmacology, phase 1, safety, tolerability, treatment, viral hepatitis, volunteers, Humans, Middle Aged, Half-Life, Male, Healthy Volunteers, Young Adult, RNA Interference, Adult, Female, Histamine Antagonists/administration \& dosage, Double-Blind Method, Hepatitis B, Chronic/drug therapy, Pre-Exposure Prophylaxis/methods, Antiviral Agents/administration \& dosage, Infusions, Intravenous",
author = "Thomas Schluep and Jason Lickliter and James Hamilton and Lewis, \{David L.\} and Lai, \{Ching Lung\} and Lau, \{Johnson Y.N.\} and Locarnini, \{Stephen A.\} and Gish, \{Robert G.\} and Given, \{Bruce D.\}",
note = "{\textcopyright} 2016 The Authors. Clinical Pharmacology in Drug Development Published by Wiley Periodicals, Inc. on behalf of The American College of Clinical Pharmacology.",
year = "2017",
month = jul,
day = "1",
doi = "10.1002/cpdd.318",
language = "English",
volume = "6",
pages = "350--362",
journal = "Clinical Pharmacology in Drug Development",
issn = "2160-763X",
number = "4",
}